Bicara Therapeutics BCAX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| —— | —— | $33M+108% | $24.8M+57.0% | $34.3M+186% | ||
| $12.74M+70.9% | $8.13M+20.4% | $7.7M+61.6% | $7.22M+84.7% | $7.46M+123% | ||
| $60.24M+44.2% | $41.12M+54.4% | $40.68M+97.2% | $32.02M+62.1% | $41.79M+172% | ||
| -$60.24M-44.2% | -$41.12M-54.4% | -$40.68M-97.2% | -$32.02M-62.1% | -$41.79M-172% | ||
| $4.08M-18.6% | $3.79M-35.4% | $4.39M+39.4% | $4.68M+73.3% | $5.01M+74.9% | ||
| -$56.16M-52.7% | -$37.33M-79.7% | -$36.29M-108% | -$27.34M-60.3% | -$36.77M-194% | ||
| $52K-27.8% | $53K-71.5% | $40K— | $52K— | $72K+7,100% | ||
| -$56.21M-52.6% | -$37.39M-78.4% | -$36.33M-108% | -$27.39M-60.6% | -$36.85M-195% | ||
| -$0.93-36.8% | -$0.68— | -$0.67+58.1% | -$0.50+97.4% | -$0.68+96.4% | ||
| -$60.2M-44.1% | -$41.08M-54.3% | -$40.65M-97.2% | -$32M-62.1% | -$41.77M-172% | ||
| -$60.24M-44.2% | -$41.12M-54.4% | -$40.68M-97.2% | -$32.02M-62.1% | -$41.79M-172% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Bicara Therapeutics profitable?
- Bicara Therapeutics is not currently profitable: it reported a net loss of $157.3M over the trailing twelve months.
- What is Bicara Therapeutics's earnings per share?
- Bicara Therapeutics's diluted EPS over the trailing twelve months is $-2.78.
- Where does Bicara Therapeutics's income statement data come from?
- Every line is extracted from Bicara Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.